Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease
April 20, 2023 07:00 ET
|
Orphalan
Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to penicillamine — Oral administration offers dosing flexibility and...
Orphalan announces publication of results from the CHELATE trial in The Lancet Gastroenterology & Hepatology
September 30, 2022 07:00 ET
|
Orphalan
Orphalan announces publication of results from the CHELATE trial in The Lancet Gastroenterology & Hepatology Trial supported Orphalan’s successful application to the United States Food and Drug...
Orphalan announces publication of results from the CHELATE trial in The Lancet Gastroenterology & Hepatology
September 30, 2022 02:00 ET
|
Orphalan
Orphalan announces publication of results from the CHELATE trial in The Lancet Gastroenterology & Hepatology Trial supported Orphalan’s successful application to the United States Food and Drug...
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”)
July 26, 2022 07:00 ET
|
Orphalan
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”) World’s first global Wilson’s Registry will provide an international...
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”)
July 26, 2022 02:00 ET
|
Orphalan
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”) World’s first global Wilson’s Registry will provide an international...
Orphalan announces data from secondary analyses of the CHELATE trial for maintenance patients with Wilson’s Disease
June 22, 2022 03:00 ET
|
Orphalan
Orphalan announces data from secondary analyses of the CHELATE trial for maintenance patients with Wilson’s Disease — Data from the company’s CHELATE trial to be presented today during an oral...
Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine
May 02, 2022 07:00 ET
|
Orphalan
Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine Paris, France 2 May 2022 – Orphalan SA...
Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine
May 02, 2022 02:00 ET
|
Orphalan
Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine Paris, France 2 May 2022 – Orphalan SA...
Orphalan strengthens its management team with two key appointments
February 01, 2022 02:00 ET
|
Orphalan
Orphalan strengthens its management team with two key appointments Paris, France 1 February 2022 – Orphalan SA, a Company that identifies, develops, and delivers therapies worldwide for orphan...
Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease
September 02, 2021 02:00 ET
|
Orphalan
Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease —NDA supported by positive data from...